BR0013162A - Formulações de hormÈnio de crescimento - Google Patents

Formulações de hormÈnio de crescimento

Info

Publication number
BR0013162A
BR0013162A BR0013162-8A BR0013162A BR0013162A BR 0013162 A BR0013162 A BR 0013162A BR 0013162 A BR0013162 A BR 0013162A BR 0013162 A BR0013162 A BR 0013162A
Authority
BR
Brazil
Prior art keywords
growth hormone
formulations
storage
hormone formulations
growth
Prior art date
Application number
BR0013162-8A
Other languages
English (en)
Inventor
Bernhard Siebold
John Stevens
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0013162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of BR0013162A publication Critical patent/BR0013162A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Abstract

"FORMULAçõES DE HORMÈNIO DE CRESCIMENTO". Formulações de hormónio de crescimento líquidas são estáveis em armazenamento por mais do que seis meses em temperaturas no limite de 2-8<198>C simplesmente formulando hormónios de crescimento em tampão de tosfato sem nenhum outro aditivo em torno de pH fisiológico. Assegurando um pH de aproximadamente 6,2 ou mais, cristalização de hormónio de crescimento durante armazenamento em temperaturas de refrigeração ou acima é inibida ou reduzida. Baixas concentrações de tensoativo não-iónico podem ajudar a reduzir agregação de hormónio de crescimento surgindo como um resultado de forças físicas encontradas durante transferência automatizada de formulação volumosa em recipientes de armazenamento. Manitol é incluído a fim de fornecer uma formulação isotónica. Conservantes são incluídos para reduzir contaminação bacterial e desse modo permitir unidades de dosagem múltiplas as quais podem ser armazenadas a 2-8<198>C.
BR0013162-8A 1999-07-12 2000-07-11 Formulações de hormÈnio de crescimento BR0013162A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (1)

Publication Number Publication Date
BR0013162A true BR0013162A (pt) 2002-05-28

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013162-8A BR0013162A (pt) 1999-07-12 2000-07-11 Formulações de hormÈnio de crescimento

Country Status (25)

Country Link
US (1) US20060029635A1 (pt)
EP (1) EP1194170B1 (pt)
JP (3) JP2003504346A (pt)
KR (1) KR20020031388A (pt)
CN (1) CN1360506A (pt)
AR (1) AR024728A1 (pt)
AT (1) ATE386501T1 (pt)
AU (1) AU775107C (pt)
BR (1) BR0013162A (pt)
CA (1) CA2378949C (pt)
CZ (1) CZ200260A3 (pt)
DE (1) DE60038118T2 (pt)
ES (1) ES2300268T3 (pt)
HK (1) HK1046358A1 (pt)
HU (1) HUP0202189A3 (pt)
IL (2) IL147253A0 (pt)
MX (1) MXPA02000404A (pt)
NO (1) NO20020151L (pt)
NZ (1) NZ516507A (pt)
PL (1) PL353238A1 (pt)
SI (1) SI1194170T1 (pt)
SK (1) SK252002A3 (pt)
TR (1) TR200200034T2 (pt)
TW (1) TWI247608B (pt)
WO (1) WO2001003741A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
AR040529A1 (es) * 2002-07-09 2005-04-13 Grandis Biotech Gmbh Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
CA2516314C (en) * 2003-03-18 2012-01-03 Ares Trading Sa Liquid growth hormone formulation and process of preparation thereof
CA2540172A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
ATE554792T1 (de) * 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
DK1740213T3 (da) * 2004-04-07 2012-04-10 Ares Trading Sa Væskeformulering til væksthormoner
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
IN2012DN02861A (pt) * 2009-11-17 2015-07-24 Ipsen Pharma Sas
JP6363949B2 (ja) 2011-07-25 2018-07-25 サンド アクチェンゲゼルシャフト 少なくとも中性塩および生物薬学的タンパク質を含む、水性製剤
EP2659902A1 (en) * 2012-04-30 2013-11-06 Sun Pharmaceutical Industries Limited Leuprolide injection
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
US10647819B2 (en) 2015-12-10 2020-05-12 Mitsubishi Gas Chemical Company, Inc. Photocurable composition and optical material
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
AU6073386A (en) * 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
AU8544191A (en) * 1990-09-21 1992-04-15 Novo Nordisk A/S Adaptor top
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
NZ255158A (en) * 1992-07-31 1997-09-22 Genentech Inc Human growth hormone; stable pharmaceutically acceptable aqueous formulation and means for preparing and storing it
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
CA2246265A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
JP2003504346A (ja) 2003-02-04
AR024728A1 (es) 2002-10-23
HK1046358A1 (zh) 2003-01-10
DE60038118D1 (de) 2008-04-03
NO20020151L (no) 2002-03-12
EP1194170A1 (en) 2002-04-10
MXPA02000404A (es) 2004-05-21
NZ516507A (en) 2004-02-27
SI1194170T1 (sl) 2008-10-31
EP1194170B1 (en) 2008-02-20
TR200200034T2 (tr) 2002-05-21
WO2001003741A1 (en) 2001-01-18
US20060029635A1 (en) 2006-02-09
AU775107C (en) 2005-02-24
ATE386501T1 (de) 2008-03-15
HUP0202189A2 (en) 2002-10-28
PL353238A1 (en) 2003-11-03
IL147253A (en) 2007-07-24
DE60038118T2 (de) 2009-03-05
CZ200260A3 (cs) 2002-04-17
TWI247608B (en) 2006-01-21
AU5997500A (en) 2001-01-30
CN1360506A (zh) 2002-07-24
ES2300268T3 (es) 2008-06-16
JP5941496B2 (ja) 2016-06-29
CA2378949A1 (en) 2001-01-18
JP2014208656A (ja) 2014-11-06
HUP0202189A3 (en) 2003-07-28
KR20020031388A (ko) 2002-05-01
SK252002A3 (en) 2002-06-04
WO2001003741B1 (en) 2001-04-19
NO20020151D0 (no) 2002-01-11
IL147253A0 (en) 2002-08-14
JP2012051891A (ja) 2012-03-15
CA2378949C (en) 2015-03-31
AU775107B2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
BR0013162A (pt) Formulações de hormÈnio de crescimento
AR040526A1 (es) Formulaciuones de hgh en alta concentracion que contienen fenol
US9655898B2 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
NZ602392A (en) Stable bortezomib formulations
EP3169313B1 (en) A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
US20140024691A1 (en) Formulations of bendamustine
SA06270332B1 (ar) تكوين hFSF مائي
WO2002080883A3 (en) Method and composition for solubilising a biologically active compound with low water solubility
CN102014920B (zh) 滴眼剂制剂及其应用
US6686365B2 (en) Pharmaceutical composition
MY173867A (en) Process to minimize polymorphism
JP2011504881A (ja) モキシフロキサシンおよびデキサメタゾンリン酸エステルを含む局所眼用または局所耳用溶液製剤
CZ20022654A3 (cs) Farmaceutická kompozice, obsahující Pemetrexed společně s monothioglycerolem, L-cysteinem nebo kyselinou thioglykolovou
BRPI0418115A (pt) formulação lìquida estável de hormÈnio de crescimento
EP0539408B1 (en) Stable pharmaceutical compositions containing a fibroblast growth factor
Fau et al. Effect of excess dietary methionine on weight gain and plasma amino acids in kittens
CN113229288A (zh) 一种新型低温冷链季铵盐消毒剂及其制备方法
JP2007224004A (ja) 超小型豚の人工授精用精液の希釈保存剤。
WO2004084629A1 (fr) Procede de lyophilisation et de cryoconservation de cals et cryoprotecteur utilise
BR112021011290A2 (pt) Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf
Webb et al. Macrophage-like suppressor cells in rats: I. Inhibition of natural macrophage-like suppressor cells by red blood cells
CA1289472C (en) Tpa-containing medical composition
JP4610154B2 (ja) 注射用製剤
Atkinson et al. ANTIBACTERIAL SUBSTANCES PRODUCED BY MOULDS 5. THE MECHANISM OF THE ACTION OF SOME PENICIDIN SUPPRESSORS.
Chow et al. Gluconeogenic dependence on ketogenesis in isolated sheep hepatocytes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.